

Form PTO-1449  INFORMATION DISCLOSURE STATEMENT				Attorney's Docket No. <b>GNE-0321C2</b>		Application Serial No. <b>10/010,245</b>	
(use several sheets if necessary)				Applicant(s)  <div style="text-align: right;">Carter</div>		Group Art Unit: <b>1645</b>	
				Filing Date: <b>December 7, 2001</b>			
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.						
	2.						
	3.						
	4.						
	5.						
	6.						
	7.						
	8.						
	9.						
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Translation YES      NO
<b>OTHER DOCUMENTS</b> (including author, title, date, pertinent pages, etc.)							
Examiner Initials	Ref. No.	Title					
	1.	Abstract: Jefferies, et al. <i>IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation</i> , Immunol. Rev. 1998 June; 163:59-76					
	2.	Thies, et al.; <i>Folding and association of the antibody domain CH3: prolyl isomerization precedes dimerization</i> , J. Mol. Biol. 1999 Oct. 15; 293(1):67-79					

LIBC/3556408.1  
09/26/2008

EXAMINER: /Stephen Gucker/	DATE CONSIDERED: 08/04/2009
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SG/